Alzheimers Disease Clinical Trials Near You

Alzheimer's research has entered a transformative era following the approval of anti-amyloid antibodies. Lecanemab (Leqembi) demonstrated a 27% slowing of cognitive decline in early-stage Alzheimer's, and donanemab showed similar efficacy with the possibility of stopping treatment once amyloid plaques are sufficiently cleared. Current trials are exploring whether these drugs work better when started even earlier — in preclinical Alzheimer's, before memory symptoms appear.

Beyond amyloid, tau-targeted therapies represent the next frontier. Phase 2 trials are testing anti-tau antibodies (semorinemab, zagotenemab, E2814) and tau aggregation inhibitors. Since tau neurofibrillary tangles correlate more closely with cognitive symptoms than amyloid plaques, successful tau therapies could provide more meaningful clinical benefit.

Combination therapy trials — targeting amyloid AND tau simultaneously — are now enrolling. Additionally, GLP-1 receptor agonists (semaglutide, liraglutide) are being tested for neuroprotective effects based on data showing 20–30% lower dementia rates in diabetic patients taking these medications.

Blood-based biomarker screening has revolutionized trial enrollment. Plasma p-tau217 and amyloid beta ratio tests can identify Alzheimer's pathology with a simple blood draw, replacing expensive PET scans ($5,000+) and invasive lumbar punctures.

Patient considerations: Trials typically require a study partner (spouse, adult child) who attends visits and reports on daily functioning. Anti-amyloid therapies carry ARIA risk (amyloid-related imaging abnormalities) — brain edema or microbleeds on MRI — requiring regular brain imaging, especially in the first 6 months. APOE4 gene carriers face higher ARIA risk and should discuss this with the research team.